Growth hormone-binding protein

Last updated
growth hormone receptor
Identifiers
SymbolGHR
NCBI gene 2690
HGNC 4263
OMIM 600946
RefSeq NM_000163
UniProt P10912
Other data
Locus Chr. 5 p13-p12
Search for
Structures Swiss-model
Domains InterPro

Growth hormone-binding protein (GHBP) is a soluble carrier protein for growth hormone (GH). [1] The full range of functions of GHBP remains to be determined. [2] [3] However, current research suggests that the protein is associated with regulation of the GH availability and half-life in the circulatory system, as well as modulating GH receptor function. [4]

Contents

Expression

In humans, GHBP is formed by post-translational modification after the complete transcription and translation of the growth hormone receptor (GHR) gene into the cell-surface receptor protein. The gene that codes for GHR (and inherently GHBP) is on Chromosome 5. [5] A precursor messenger RNA (mRNA) from the complete gene first is transcribed and then spliced to encode the full receptor protein. This mature mRNA is composed of exons. Exons are peptide encoding regions of DNA genes that remain in the transcript after splicing and during the maturation of mRNA. The mRNA transcript encodes for a receptor protein that is made up of three distinct parts: an intracellular domain, a transmembrane domain, and an extracellular domain. [6] Specifically, part of exon 2 and exons 3-7 of the GHR gene will translate to amino acids that make up the extracellular domain of GHR. This extracellular domain physically binds GH in the receptor-ligand interaction. [4]

"Receptor Ectodomain Shedding" - Tumor-necrosis factor alpha converting enzyme (T.A.C.E.) proteolytically cleaves the extracellular domain off of (two) growth hormone receptor(s) to release the soluble carrier-protein growth hormone-binding protein. Adapted from Fisker. Growth Hormone Receptor Ectodomain Shedding.png
"Receptor Ectodomain Shedding" - Tumor-necrosis factor alpha converting enzyme (T.A.C.E.) proteolytically cleaves the extracellular domain off of (two) growth hormone receptor(s) to release the soluble carrier-protein growth hormone-binding protein. Adapted from Fisker.

In rodents and in humans the concentration GHR mRNA and the concentration of GHBP in the maternal circulation are dramatically increased during pregnancy. [8] [9] This is considered likely to control the availability of GH for binding to GH receptors in the maternal tissues during pregnancy. [10]

Receptor ectodomain shedding

When the extracellular domain of GHR is proteolytically cleaved (see: proteolytic cleavage) from the rest of the receptor protein, the extracellular domain is released as the water-soluble, carrier protein GHBP. [11] [12] [13] As the extracellular domain alone, the polypeptide consists of 246 amino acids [4] and is roughly 60 kDA in size. [14] This cleaving process is called “receptor ectodomain shedding. [15] In humans and rabbits, tumor-necrosis factor alpha converting enzyme (T.A.C.E.) is postulated to play a significant role in the post-translational processing activity that sheds GHBP from GHR. [16] [17] Studies show that this activity primarily occurs in the liver. [18] When growth hormone is bound to two dimerized GH receptors, the shedding activity is inhibited. This occurs because when the ligand binds to the receptors, a conformational change occurs in them that potentially blocks the proteolytic activity of T.A.C.E. [17] [19]

Alternative splicing

In humans, studies have shown that alternative splicing of the GHR gene can lead to increased rates of proteolysis. For example, a deletion within the mRNA that encodes part of the transmembrane domain of the protein effectively leads to non-translation of the intracellular domain due to the presence of a stop codon. [20] This truncated version of GHR is cleaved more frequently into GHBP and may potentially explain the reasoning behind increased concentrations of GHBP present in some tissues. [21]

In mouse and rat models, the extracellular domain is formed primarily through alternative splicing of the precursor GHR mRNA to form a mature transcript that translate GHBP alone. These animals can potentially shed GHBP via post-translational modification as well, although this activity is minimal. [17] [22]

Function

Two growth hormone-binding proteins (blue, pink) in a two-to-one ratio with growth hormone (green). Source: PDB 1HWG GHBP in 2-1 ratio with GH.png
Two growth hormone-binding proteins (blue, pink) in a two-to-one ratio with growth hormone (green). Source: PDB 1HWG

The full range of physiological consequences of GHBP binding GH is not known , [23] however literature provides evidence that the carrier-protein prolongs the half-life of growth hormone through its binding with the ligand. [24]

Binding stoichiometry

Growth hormone binds to GHBP and GHR via an interactive region of helices 1 and 4 of GH. [25] Two receptor molecules are pre-dimerized upon GH binding, so it always binds in a 1:2 ratio. [26] Assays estimate that growth hormone and growth hormone binding protein form a natural complex at a 1:1 ratio for transport and preservation of the ligand through the bloodstream. [27] [28] However, some sources have shown that high physiological concentration of GHBP will result in a 1:2 ratio. [29] [30] When the cysteine amino acids in GHBP are mutated and the disulfide bridges are disrupted, the ability of the ligand to bind to the active site of the GHBP is significantly lessened. [31]

Activation

Growth-hormone binding protein (blue) in a one-to-one ratio with modified growth hormone (green). Source: PDB 1HWH GHBP in 1-1 ratio with GH.png
Growth-hormone binding protein (blue) in a one-to-one ratio with modified growth hormone (green). Source: PDB 1HWH

The clearance rate, or the rate at which the carrier protein is broken down, for GHBP alone is much faster than when it is bound to its ligand. [4] Additionally, current literature provides evidence that the carrier-protein prolongs the half-life of growth hormone through its binding with the ligand. [24] One purpose of GHBP can be inferred: to maintain the level of GH in the blood, as roughly half of its concentration is complexed with GHBP. [32] Yet this could be confounded by the fact that GH binding to GHBP prevents the ligand from binding to GHR and ultimately proteolytic activity. [33] Another function is that GHBP displays competitive inhibition for GH against the GHR receptor. [18]

Studies elucidate another aspect of GHBP physiological role: The proteolytic cleavage activity that forms GHBP ultimately regulates GHR production in humans as well as rats. [19] [34] If there is low GHBP concentration then there are high levels of GHR expression. Conversely, high levels of GHBP protein show negative correlation with levels of growth hormone receptor expression. [18] [35]

Isoforms

Exon 3

Studies have identified a GHBP isoform that exists due to gene polymorphism, or variable expression of the allele. These isoforms differ based on whether or not the extracellular domain of GHR includes the amino acids encoded by exon 3 - exon 3 is either kept (dominant) or spliced out (recessive). [36] As human are diploid, they may genotype as homozygous dominant (two copies of the allele retain exon 3), heterozygous (one copy with Exon 3, and one without), or homozygous recessive (two copies of the allele without exon 3). [37] Studies have shown that the two isoforms can co-exist as dimerized GH receptors, as E3+/E3+, E3+/E3-, or E3-/E3-. [36]

Furthermore, the two isoforms both exist in the blood as GHBP. However, they may have separate functions that are poorly understood. The presence or absence of exon 3 in humans is individual-specific, but one study suggests that gender may play a role in this variable splicing, as females were shown to express higher levels of deleted-exon 3 GHBP in their blood. [38] The evolutionary reason for exon-3 variable GHBP expression has not clearly be defined, and the isoforms in the blood have not been shown to differ with respect to GH affinity, which is unusual for an isoform that is missing an entire exon. [39]

Related Research Articles

<span class="mw-page-title-main">Insulin receptor</span> Cell receptor found in humans

The insulin receptor (IR) is a transmembrane receptor that is activated by insulin, IGF-I, IGF-II and belongs to the large class of receptor tyrosine kinase. Metabolically, the insulin receptor plays a key role in the regulation of glucose homeostasis; a functional process that under degenerate conditions may result in a range of clinical manifestations including diabetes and cancer. Insulin signalling controls access to blood glucose in body cells. When insulin falls, especially in those with high insulin sensitivity, body cells begin only to have access to lipids that do not require transport across the membrane. So, in this way, insulin is the key regulator of fat metabolism as well. Biochemically, the insulin receptor is encoded by a single gene INSR, from which alternate splicing during transcription results in either IR-A or IR-B isoforms. Downstream post-translational events of either isoform result in the formation of a proteolytically cleaved α and β subunit, which upon combination are ultimately capable of homo or hetero-dimerisation to produce the ≈320 kDa disulfide-linked transmembrane insulin receptor.

<span class="mw-page-title-main">Insulin-like growth factor 1</span> Protein found in humans

Insulin-like growth factor 1 (IGF-1), also called somatomedin C, is a hormone similar in molecular structure to insulin which plays an important role in childhood growth, and has anabolic effects in adults. In the 1950s IGF-1 was called "sulfation factor" because it stimulated sulfation of cartilage in vitro, and in the 1970s due to its effects it was termed "nonsuppressible insulin-like activity" (NSILA).

<span class="mw-page-title-main">Sex hormone-binding globulin</span> Human glycoprotein that binds to androgens and estrogens

Sex hormone-binding globulin (SHBG) or sex steroid-binding globulin (SSBG) is a glycoprotein that binds to androgens and estrogens. When produced by the Sertoli cells in the seminiferous tubules of the testis, it is called androgen-binding protein (ABP).

The prolactin receptor (PRLR) is a type I cytokine receptor encoded in humans by the PRLR gene on chromosome 5p13-14. It is the receptor for prolactin (PRL). The PRLR can also bind to and be activated by growth hormone (GH) and human placental lactogen (hPL). The PRLR is expressed in the mammary glands, pituitary gland, and other tissues. It plays an important role in lobuloalveolar development of the mammary glands during pregnancy and in lactation.

<span class="mw-page-title-main">Luteinizing hormone/choriogonadotropin receptor</span> Transmembrane receptor found in humans

The luteinizing hormone/choriogonadotropin receptor (LHCGR), also lutropin/choriogonadotropin receptor (LCGR) or luteinizing hormone receptor (LHR), is a transmembrane receptor found predominantly in the ovary and testis, but also many extragonadal organs such as the uterus and breasts. The receptor interacts with both luteinizing hormone (LH) and chorionic gonadotropins and represents a G protein-coupled receptor (GPCR). Its activation is necessary for the hormonal functioning during reproduction.

<span class="mw-page-title-main">Thyrotropin receptor</span> Mammalian protein found in Homo sapiens

The thyrotropin receptor is a receptor that responds to thyroid-stimulating hormone and stimulates the production of thyroxine (T4) and triiodothyronine (T3). The TSH receptor is a member of the G protein-coupled receptor superfamily of integral membrane proteins and is coupled to the Gs protein.

<span class="mw-page-title-main">Growth hormone receptor</span> A protein involved in the binding of the growth hormone

Growth hormone receptor is a protein that in humans is encoded by the GHR gene. GHR orthologs have been identified in most mammals.

<span class="mw-page-title-main">Laron syndrome</span> Medical condition

Laron syndrome (LS), also known as growth hormone insensitivity or growth hormone receptor deficiency (GHRD), is an autosomal recessive disorder characterized by a lack of insulin-like growth factor 1 production in response to growth hormone. It is usually caused by inherited growth hormone receptor (GHR) mutations.

<span class="mw-page-title-main">Growth-hormone-releasing hormone receptor</span> Receptor protein that binds with somatcrinin

The growth-hormone-releasing hormone receptor (GHRHR) is a G-protein-coupled receptor that binds growth hormone-releasing hormone. The GHRHR activates a Gs protein that causes a cascade of cAMP via adenylate cyclase. GHRHR is distinct from the growth hormone secretagogue receptor, where growth hormone releasing peptides act to release growth hormone.

<span class="mw-page-title-main">Rev-ErbA beta</span> Protein-coding gene in the species Homo sapiens

Rev-Erb beta (Rev-Erbβ), also known as nuclear receptor subfamily 1 group D member 2 (NR1D2), is a member of the Rev-Erb protein family. Rev-Erbβ, like Rev-Erbα, belongs to the nuclear receptor superfamily of transcription factors and can modulate gene expression through binding to gene promoters. Together with Rev-Erbα, Rev-Erbβ functions as a major regulator of the circadian clock. These two proteins are partially redundant. Current research suggests that Rev-Erbβ is less important in maintaining the circadian clock than Rev-Erbα; knock-out studies of Rev-Erbα result in significant circadian disruption but the same has not been found with Rev-Erbβ. Rev-Erbβ compensation for Rev-Erbα varies across tissues, and further research is needed to elucidate the separate role of Rev-Erbβ.

<span class="mw-page-title-main">IGFBP3</span> Protein-coding gene in the species Homo sapiens

Insulin-like growth factor-binding protein 3, also known as IGFBP-3, is a protein that in humans is encoded by the IGFBP3 gene. IGFBP-3 is one of six IGF binding proteins that have highly conserved structures and bind the insulin-like growth factors IGF-1 and IGF-2 with high affinity. IGFBP-7, sometimes included in this family, shares neither the conserved structural features nor the high IGF affinity. Instead, IGFBP-7 binds IGF1R, which blocks IGF-1 and IGF-2 binding, resulting in apoptosis.

<span class="mw-page-title-main">Parathyroid hormone 1 receptor</span> Protein-coding gene in the species Homo sapiens

Parathyroid hormone/parathyroid hormone-related peptide receptor, also known as parathyroid hormone 1 receptor (PTH1R), is a protein that in humans is encoded by the PTH1R gene. PTH1R functions as a receptor for parathyroid hormone (PTH) and for parathyroid hormone-related protein (PTHrP), also called parathyroid hormone-like hormone (PTHLH).

<span class="mw-page-title-main">Somatostatin receptor 2</span> Protein-coding gene in the species Homo sapiens

Somatostatin receptor type 2 is a protein that in humans is encoded by the SSTR2 gene.

<span class="mw-page-title-main">Corticotropin-releasing hormone receptor 1</span> Protein and coding gene in humans

Corticotropin-releasing hormone receptor 1 (CRHR1) is a protein, also known as CRF1, with the latter (CRF1) now being the IUPHAR-recommended name. In humans, CRF1 is encoded by the CRHR1 gene at region 17q21.31, beside micrototubule-associated protein tau MAPT.

<span class="mw-page-title-main">Thyroid hormone receptor beta</span> Protein-coding gene in the species Homo sapiens

Thyroid hormone receptor beta (TR-beta) also known as nuclear receptor subfamily 1, group A, member 2 (NR1A2), is a nuclear receptor protein that in humans is encoded by the THRB gene.

<span class="mw-page-title-main">Corticotropin-releasing hormone receptor 2</span> Protein found in humans

Corticotropin-releasing hormone receptor 2 (CRHR2) is a protein, also known by the IUPHAR-recommended name CRF2, that is encoded by the CRHR2 gene and occurs on the surfaces of some mammalian cells. CRF2 receptors are type 2 G protein-coupled receptors for corticotropin-releasing hormone (CRH) that are resident in the plasma membranes of hormone-sensitive cells. CRH, a peptide of 41 amino acids synthesized in the hypothalamus, is the principal neuroregulator of the hypothalamic-pituitary-adrenal axis, signaling via guanine nucleotide-binding proteins (G proteins) and downstream effectors such as adenylate cyclase. The CRF2 receptor is a multi-pass membrane protein with a transmembrane domain composed of seven helices arranged in a V-shape. CRF2 receptors are activated by two structurally similar peptides, urocortin II, and urocortin III, as well as CRH.

<span class="mw-page-title-main">Growth hormone 2</span> Variant of somatotropin produced by placenta

Growth hormone 2 (GH2), also known more commonly as placental growth hormone (PGH) or growth hormone variant (GH-V), is a protein that in humans is encoded by the GH2 gene. It is produced by and secreted from the placenta during pregnancy, and becomes the predominant form of growth hormone (GH) in the body during this time. Its cogener is growth hormone 1 (GH1), or pituitary growth hormone.

<span class="mw-page-title-main">TSHB</span> Protein-coding gene in the species Homo sapiens

Thyroid stimulating hormone, beta also known as TSHB is a protein which in humans is encoded by the TSHB gene.

<span class="mw-page-title-main">Kowarski syndrome</span> Medical condition

Kowarski syndrome describes cases of growth failure, despite the presence of normal or slightly high blood growth hormone by radioimmunoassay (RIA-GH) and low serum IGF1, and who exhibit a significant increase in growth rate following recombinant GH therapy.

<span class="mw-page-title-main">Examorelin</span> Chemical compound

Examorelin (INN) (developmental code names EP-23905, MF-6003), also known as hexarelin, is a potent, synthetic, peptidic, orally-active, centrally-penetrant, and highly selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) and a growth hormone secretagogue which was developed by Mediolanum Farmaceutici. It is a hexapeptide with the amino acid sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 which was derived from GHRP-6. These GH-releasing peptides have no sequence similarity to ghrelin, but mimic ghrelin by acting as agonists at the ghrelin receptor.

References

  1. ↑ Baumann G (Dec 2002). "Growth hormone binding protein. The soluble growth hormone receptor". Minerva Endocrinologica. 27 (4): 265–76. PMID   12511849.
  2. ↑ Baumann G, Stolar MW, Amburn K, Barsano CP, DeVries BC (Jan 1986). "A specific growth hormone-binding protein in human plasma: initial characterization". The Journal of Clinical Endocrinology and Metabolism. 62 (1): 134–41. doi:10.1210/jcem-62-1-134. PMID   3940261.
  3. ↑ Baumann G (1999). "Growth Hormone Binding Proteins". In Bengtsson BÅ (ed.). Growth Hormone. Endocrine Updates. Vol. 4. Springer. pp. 37–57. doi:10.1007/978-1-4615-5163-8_3. ISBN   978-1-4613-7351-3.
  4. 1 2 3 4 Schilbach K, Bidlingmaier M (2015). "Growth hormone binding protein - physiological and analytical aspects". Best Practice & Research. Clinical Endocrinology & Metabolism. 29 (5): 671–83. doi:10.1016/j.beem.2015.06.004. PMID   26522453.
  5. ↑ Barton DE, Foellmer BE, Wood WI, Francke U (1989). "Chromosome mapping of the growth hormone receptor gene in man and mouse". Cytogenetics and Cell Genetics. 50 (2–3): 137–41. doi:10.1159/000132743. PMID   2776481.
  6. ↑ "GHR growth hormone receptor [Homo sapiens (human)]". NCBI.
  7. ↑ Fisker S (Feb 2006). "Physiology and pathophysiology of growth hormone-binding protein: methodological and clinical aspects". Growth Hormone & IGF Research. 16 (1): 1–28. doi:10.1016/j.ghir.2005.11.001. PMID   16359897.
  8. ↑ Smith WC, Talamantes F (Sep 1988). "Gestational profile and affinity cross-linking of the mouse serum growth hormone-binding protein". Endocrinology. 123 (3): 1489–1494. doi:10.1210/endo-123-3-1489. PMID   340293.
  9. ↑ Cramer SD, Barnard R, Engbers C, Ogren L, Talamantes F (Aug 1992). "Expression of the growth hormone receptor and growth hormone-binding protein during pregnancy in the mouse". Endocrinology. 131 (2): 876–882. doi:10.1210/endo.131.2.1639029. PMID   1639029.
  10. ↑ McIntyre HD, Serek R, Crane DI, Veveris-Lowe T, Parry A, Johnson S, Leung KC, Ho KK, Bougoussa M, Hennen G, Igout A, Chan FY, Cowley D, Cotterill A, Barnard R (Mar 2000). "Placental growth hormone (GH), GH-binding protein, and insulin-like growth factor axis in normal, growth-retarded, and diabetic pregnancies: correlations with fetal growth". J Clin Endocrinol Metab. 85 (3): 1143–1150. doi: 10.1210/jcem.85.3.6480 . PMID   10720053. S2CID   11993597.
  11. ↑ Leung DW, Spencer SA, Cachianes G, Hammonds RG, Collins C, Henzel WJ, Barnard R, Waters MJ, Wood WI (1987). "Growth hormone receptor and serum binding protein: purification, cloning and expression". Nature. 330 (6148): 537–43. Bibcode:1987Natur.330..537L. doi:10.1038/330537a0. PMID   2825030. S2CID   4370204.
  12. ↑ Herington AC, Ymer S, Stevenson J (Jun 1986). "Identification and characterization of specific binding proteins for growth hormone in normal human sera". J Clin Invest. 77 (6): 1817–1823. doi:10.1172/JCI112507. PMC   370539 . PMID   3711337.
  13. ↑ Barnard R, Waters MJ (Aug 1986). "Serum and liver cytosolic growth-hormone-binding proteins are antigenically identical with liver membrane 'receptor' types 1 and 2". Biochem J. 237 (3): 885–892. doi:10.1042/bj2370885. PMC   1147071 . PMID   2432878.
  14. ↑ Fisker S (2006). "Physiology and pathophysiology of growth hormone-binding protein: methodological and clinical aspects". Growth Hormone & IGF Research. 16 (1): 1–28. doi:10.1016/j.ghir.2005.11.001. PMID   16359897.
  15. ↑ Alele J, Jiang J, Goldsmith JF, Yang X, Maheshwari HG, Black RA, Baumann G, Frank SJ (1998). "Blockade of growth hormone receptor shedding by a metalloprotease inhibitor". Endocrinology. 139 (4): 1927–35. doi: 10.1210/endo.139.4.5906 . PMID   9528979.
  16. ↑ Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP (1997). "A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells". Nature. 385 (6618): 729–33. Bibcode:1997Natur.385..729B. doi:10.1038/385729a0. PMID   9034190. S2CID   4251053.
  17. 1 2 3 Schantl JA, Roza M, Van Kerkhof P, Strous GJ (Jan 2004). "The growth hormone receptor interacts with its sheddase, the tumour necrosis factor-alpha-converting enzyme (TACE)". The Biochemical Journal. 377 (Pt 2): 379–84. doi:10.1042/BJ20031321. PMC   1223864 . PMID   14519102.
  18. 1 2 3 Amit T, Youdim MB, Hochberg Z (2000). "Clinical review 112: Does serum growth hormone (GH) binding protein reflect human GH receptor function?". The Journal of Clinical Endocrinology and Metabolism. 85 (3): 927–32. doi: 10.1210/jcem.85.3.6461 . PMID   10720017.
  19. 1 2 Zhang Y, Guan R, Jiang J, Kopchick JJ, Black RA, Baumann G, Frank SJ (Jul 2001). "Growth hormone (GH)-induced dimerization inhibits phorbol ester-stimulated GH receptor proteolysis". The Journal of Biological Chemistry. 276 (27): 24565–73. doi: 10.1074/jbc.M101281200 . PMID   11309389.
  20. ↑ Ross RJ, Esposito N, Shen XY, Von Laue S, Chew SL, Dobson PR, Postel-Vinay MC, Finidori J (Mar 1997). "A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein". Molecular Endocrinology. 11 (3): 265–73. doi: 10.1210/mend.11.3.9901 . PMID   9058373.
  21. ↑ Iida K, Takahashi Y, Kaji H, Nose O, Okimura Y, Abe H, Chihara K (1998). "Growth hormone (GH) insensitivity syndrome with high serum GH-binding protein levels caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain". The Journal of Clinical Endocrinology and Metabolism. 83 (2): 531–7. doi: 10.1210/jcem.83.2.4601 . PMID   9467570.
  22. ↑ Edens A, Southard JN, Talamantes F (Dec 1994). "Mouse growth hormone-binding protein and growth hormone receptor transcripts are produced from a single gene by alternative splicing". Endocrinology. 135 (6): 2802–5. doi:10.1210/endo.135.6.7988474. PMID   7988474.
  23. ↑ Postel-Vinay MC (1996). "Growth hormone- and prolactin-binding proteins: soluble forms of receptors". Hormone Research. 45 (3–5): 178–81. doi:10.1159/000184783. PMID   8964579.
  24. 1 2 Carlsson LM, Rosberg S, Vitangcol RV, Wong WL, Albertsson-Wikland K (Aug 1993). "Analysis of 24-hour plasma profiles of growth hormone (GH)-binding protein, GH/GH-binding protein-complex, and GH in healthy children". The Journal of Clinical Endocrinology and Metabolism. 77 (2): 356–61. doi:10.1210/jcem.77.2.8345039. PMID   8345039.
  25. ↑ de Vos AM, Ultsch M, Kossiakoff AA (Jan 1992). "Human growth hormone and extracellular domain of its receptor: crystal structure of the complex". Science. 255 (5042): 306–312. Bibcode:1992Sci...255..306D. doi:10.1126/science.1549776. PMID   1549776.
  26. ↑ Brooks AJ, Waters MJ (Sep 2010). "The growth hormone receptor: mechanism of activation and clinical implications". Nature Reviews. Endocrinology. 6 (9): 515–25. doi:10.1038/nrendo.2010.123. PMID   20664532. S2CID   23639819.
  27. ↑ Sundström M, Lundqvist T, Rödin J, Giebel LB, Milligan D, Norstedt G (Dec 1996). "Crystal structure of an antagonist mutant of human growth hormone, G120R, in complex with its receptor at 2.9 A resolution". The Journal of Biological Chemistry. 271 (50): 32197–203. doi: 10.1074/jbc.271.50.32197 . PMID   8943276.
  28. ↑ Goodwill D (2004). "Growth Hormone". RCSB Protein Data Bank. doi:10.2210/rcsb_pdb/mom_2004_4.
  29. ↑ Baumann G, Lowman HB, Mercado M, Wells JA (May 1994). "The stoichiometry of growth hormone-binding protein complexes in human plasma: comparison with cell surface receptors". The Journal of Clinical Endocrinology and Metabolism. 78 (5): 1113–8. doi:10.1210/jcem.78.5.8175967. PMID   8175967.
  30. ↑ de Vos AM, Ultsch M, Kossiakoff AA (Jan 1992). "Human growth hormone and extracellular domain of its receptor: crystal structure of the complex". Science. 255 (5042): 306–12. Bibcode:1992Sci...255..306D. doi:10.1126/science.1549776. PMID   1549776.
  31. ↑ Junnila RK, Wu Z, Strasburger CJ. The role of human growth hormone's C-terminal disulfide bridge. Growth Horm IGF Res. 2013;23(3):62-7
  32. ↑ Baumann G, Amburn K, Shaw MA (Mar 1988). "The circulating growth hormone (GH)-binding protein complex: a major constituent of plasma GH in man". Endocrinology. 122 (3): 976–84. doi:10.1210/endo-122-3-976. PMID   3342762.
  33. ↑ Barnard R, Waters MJ (1997). "The serum growth hormone binding protein: pregnant with possibilities". The Journal of Endocrinology. 153 (1): 1–14. doi:10.1677/joe.0.1530001. PMID   9135564.
  34. ↑ Wang X, Jiang J, Warram J, Baumann G, Gan Y, Menon RK, Denson LA, Zinn KR, Frank SJ (Jun 2008). "Endotoxin-induced proteolytic reduction in hepatic growth hormone (GH) receptor: a novel mechanism for GH insensitivity". Molecular Endocrinology. 22 (6): 1427–37. doi:10.1210/me.2007-0561. PMC   2422827 . PMID   18323468.
  35. ↑ Maheshwari H, Lillioja S, Castillo CE, Mercado M, Baumann G (1995). "Growth hormone-binding protein in human lymph". The Journal of Clinical Endocrinology and Metabolism. 80 (12): 3582–4. doi:10.1210/jcem.80.12.8530602. PMID   8530602.
  36. 1 2 Stallings-Mann ML, Ludwiczak RL, Klinger KW, Rottman F (Oct 1996). "Alternative splicing of exon 3 of the human growth hormone receptor is the result of an unusual genetic polymorphism". Proceedings of the National Academy of Sciences of the United States of America. 93 (22): 12394–9. Bibcode:1996PNAS...9312394S. doi: 10.1073/pnas.93.22.12394 . PMC   38002 . PMID   8901592.
  37. ↑ Seidel B, Glasow A, Schutt M, Kiess W, Wu Z, Strasburger CJ, Kratzsch J (Mar 2003). "Association between the GH receptor/exon 3 genotype and the level of exon 3-positive GH-binding protein in human serum". European Journal of Endocrinology. 148 (3): 317–24. doi: 10.1530/eje.0.1480317 . PMID   12611612.
  38. ↑ Kratzsch J, Wu Z, Kiess W, Dehmel B, Bosse-Henck A, Reuter W, Pflaum CD, Strasburger CJ (2001). "The exon 3-retaining and the exon 3-deleted forms of the growth hormone-binding protein (GHBP) in human serum are regulated differently". Clinical Endocrinology. 54 (1): 61–8. doi:10.1046/j.1365-2265.2001.01177.x. PMID   11167927. S2CID   23577976.
  39. ↑ Kucukhuseyin O, Toptas B, Timirci-Kahraman O, Isbir S, Karsidag K, Isbir T (2015-06-01). "The Effect of GHR/exon-3 Polymorphism and Serum GH, IGF-1 and IGFBP-3 Levels in Diabetes and Coronary Heart Disease". In Vivo. 29 (3): 371–8. PMID   25977383.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.